A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9 — Stella
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(4 sites)
United States
Florida Cancer Specialists, Orlando, Florida
Spain
Hospital Universitario HM Sanchinarro - START Madrid CIOCC, Madrid
Hospital Universitario Quironsalud Madrid - NEXT Oncology, Pozuelo de Alarcón